Regulatory Status: Where Each One Actually Stands This is the part that's most commonly out of date on other comparison pages, so it's worth being precise: Mazdutide was approved by China's NMPA in June 2025 for chronic weight management, sold domestically as Xinermei
Many people eat half a meal now and save the other half for 23 hours later
FDA approves new drug for treatment of type 2 diabetes
Compare their mechanism, effectiveness, side effects, cost, availability, and pros and cons to make an informed choice
Switching from semaglutide to tirzepatide as a one-time transition does produce additional weight loss in many patients, but this appears to be due to tirzepatide being a more effective medication overall rather than the switching itself providing benefit
Store cool and dry before reconstitution and refrigerated after mixing